This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Reasons to Retain Intuitive Surgical (ISRG) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
Is Lantheus Holdings (LNTH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and strategic deals.
HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.
Reasons to Add Allscripts (MDRX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
Catalent's (CTLT) New Project Completion Expands Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Masimo's (MASI) New Product Expansion to Boost Patient Outcome
by Zacks Equity Research
Masimo's (MASI) latest feature additions to its telehealth for Patient SafetyNet are likely to significantly improve patient outcomes.
Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal
by Zacks Equity Research
According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.
Surging Earnings Estimates Signal Upside for AllScripts (MDRX) Stock
by Zacks Equity Research
AllScripts (MDRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
PerkinElmer's (PKI) Latest Launch to Boost Food Analysis Suite
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Baxter (BAX) to Enhance Its Portfolio With Latest Partnership
by Zacks Equity Research
Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.
Zacks Investment Ideas feature highlights: Allscripts Healthcare Solutions and Change Healthcare
by Zacks Equity Research
Allscripts Healthcare Solutions and Change Healthcare are included in this investment ideas blog.
Medical IT Providers Marching to Their Own Beat
by Bryan Hayes
Medical IT Providers Marching to Their Own Beat
Reasons to Add Quidel (QDEL) Stock To Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.
Allscripts (MDRX) Unveils Newly Rebranded App Expo Site
by Zacks Equity Research
Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage
by Zacks Equity Research
Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.
Is Bayer Aktiengesellschaft (BAYRY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bayer Aktiengesellschaft (BAYRY) and AllScripts Healthcare (MDRX) have performed compared to their sector so far this year.
Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing
by Zacks Equity Research
Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.
Allscripts (MDRX) Up 4.5% Since Q4 Earnings: What's Driving It?
by Zacks Equity Research
Allscripts' (MDRX) stock rallies on better-than-expected fourth-quarter performance and recent alliances.